Soleno Therapeutics, Inc.
General ticker "SLNO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Soleno Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -3.9%.
Estimated limits based on current volatility of 3.9%: low 40.09$, high 43.35$
Factors to consider:
- Total employees count: 92 (+178.8%) as of 2024
- Top business risk factors: Lack of approved products, Dependence on DCCR, Regulatory and compliance, Operational and conduct risks, High R&D costs
- Current price 19.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [21.28$, 56.25$]
- 2025-12-31 to 2026-12-31 estimated range: [12.81$, 35.42$]
Financial Metrics affecting the SLNO estimates:
- Negative: with PPE of -10.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.80 <= 0.04
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.01 <= 0.74
- Positive: -14.19 < Investing cash flow per share per price, % of -12.41
- Positive: Inventory ratio change, % of 0 <= 0
Short-term SLNO quotes
Long-term SLNO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $24.40MM | $41.38MM | $187.67MM |
| Operating Income | $-24.40MM | $-41.38MM | $-187.67MM |
| Non-Operating Income | $0.33MM | $2.40MM | $11.82MM |
| Interest Expense | $0.00MM | $0.00MM | $0.23MM |
| R&D Expense | $15.27MM | $25.19MM | $78.57MM |
| Income(Loss) | $-24.07MM | $-38.99MM | $-175.85MM |
| Profit(Loss)* | $-24.07MM | $-38.99MM | $-175.85MM |
| Stockholders Equity | $10.35MM | $157.51MM | $245.11MM |
| Assets | $26.50MM | $180.69MM | $330.97MM |
| Operating Cash Flow | $-20.78MM | $-24.94MM | $-69.10MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.22MM |
| Investing Cash Flow | $-0.01MM | $0.00MM | $-225.68MM |
| Financing Cash Flow | $14.09MM | $180.02MM | $213.03MM |
| Earnings Per Share** | $-2.87 | $-2.36 | $-4.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.